Oral lesions, such as cheilitis or ulcerative lesions in the oral cavity, have been reported in a subset of patients with Crohn’s disease (CD) and may even precede gastrointestinal involvement.
1 Little has been published regarding therapy of oral CD, but recent case-reports describe a beneficial effect of anti-TNF-alpha antagonists.
2 Ustekinumab, an antibody targeting the p40 subunit of interleukin-12 and interleukin-23, has demonstrated efficacy in CD.
3 However, up to date ustekinumab has not been described as treatment of Crohn’s cheilitis. Here we report a case of successful treatment with ustekinumab for a severe refractory oral manifestation of CD.